Medicinal Research Reviews最新文献

Unveiling gut microbiota's role: Bidirectional regulation of drug transport for improved safety. 揭示肠道微生物群的作用：双向调节药物运输，提高安全性。

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2025-01-01 Epub Date: 2024-08-24 DOI: 10.1002/med.22077

Jinyi Wang, Tingting Zhou

{"title":"Unveiling gut microbiota's role: Bidirectional regulation of drug transport for improved safety.","authors":"Jinyi Wang, Tingting Zhou","doi":"10.1002/med.22077","DOIUrl":"10.1002/med.22077","url":null,"abstract":"Drug safety is a paramount concern in the field of drug development, with researchers increasingly focusing on the bidirectional regulation of gut microbiota in this context. The gut microbiota plays a crucial role in maintaining drug safety. It can influence drug transport processes in the body through various mechanisms, thereby modulating their efficacy and toxicity. The main mechanisms include: (1) The gut microbiota directly interacts with drugs, altering their chemical structure to reduce toxicity and enhance efficacy, thereby impacting drug transport mechanisms, drugs can also change the structure and abundance of gut bacteria; (2) bidirectional regulation of intestinal barrier permeability by gut microbiota, promoting the absorption of nontoxic drugs and inhibiting the absorption of toxic components; (3) bidirectional regulation of the expression and activity of transport proteins by gut microbiota, selectively promoting the absorption of effective components or inhibiting the absorption of toxic components. This bidirectional regulatory role enables the gut microbiota to play a key role in maintaining drug balance in the body and reducing adverse reactions. Understanding these regulatory mechanisms sheds light on novel approaches to minimize toxic side effects, enhance drug efficacy, and ultimately improve drug safety. This review systematically examines the bidirectional regulation of gut microbiota in drug transportation from the aforementioned aspects, emphasizing their significance in ensuring drug safety. Furthermore, it offers a prospective outlook from the standpoint of enhancing therapeutic efficacy and reducing drug toxicity, underscoring the importance of further exploration in this research domain. It aims to provide more effective strategies for drug development and treatment.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":" ","pages":"311-343"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pyroptosis and the fight against lung cancer. 火绒病与肺癌的斗争

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2025-01-01 Epub Date: 2024-08-12 DOI: 10.1002/med.22071

Jiwei Wang, Huiling Su, Min Wang, Richard Ward, Su An, Tian-Rui Xu

{"title":"Pyroptosis and the fight against lung cancer.","authors":"Jiwei Wang, Huiling Su, Min Wang, Richard Ward, Su An, Tian-Rui Xu","doi":"10.1002/med.22071","DOIUrl":"10.1002/med.22071","url":null,"abstract":"Pyroptosis, a newly characterized type of inflammatory programmed cell death (PCD), is usually triggered by multiple inflammasomes which can recognize different danger or damage-associated molecular patterns (DAMPs), leading to the activation of caspase-1 and the cleavage of gasdermin D (GSDMD). Gasdermin family pore-forming proteins are the executers of pyroptosis and are normally maintained in an inactive state through auto-inhibition. Upon caspases mediated cleavage of gasdermins, the pro-pyroptotic N-terminal fragment is released from the auto-inhibition of C-terminal fragment and oligomerizes, forming pores in the plasma membrane. This results in the secretion of interleukin (IL)-1β, IL-18, and high-mobility group box 1 (HMGB1), generating osmotic swelling and lysis. Current therapeutic approaches including chemotherapy, radiotherapy, molecularly targeted therapy and immunotherapy for lung cancer treatment efficiently force the cancer cells to undergo pyroptosis, which then generates local and systemic antitumor immunity. Thus, pyroptosis is recognized as a new therapeutic regimen for the treatment of lung cancer. In this review, we briefly describe the signaling pathways involved in pyroptosis, and endeavor to discuss the antitumor effects of pyroptosis and its potential application in lung cancer therapy, focusing on the contribution of pyroptosis to microenvironmental reprogramming and evocation of antitumor immune response.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":" ","pages":"5-28"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141915641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fenamates: Forgotten treasure for cancer treatment and prevention: Mechanisms of action, structural modification, and bright future. 非那明酸盐：被遗忘的癌症治疗和预防宝藏：作用机制、结构改造和光明前景。

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2025-01-01 Epub Date: 2024-08-22 DOI: 10.1002/med.22079

Junfang Li, Xiaodong Wang, Honghua Zhang, Xiaoling Hu, Xue Peng, Weifan Jiang, Linsheng Zhuo, Yan Peng, Guo Zeng, Zhen Wang

引用次数: 0

Targeting tumor microenvironment with photodynamic nanomedicine. 用光动力纳米药物靶向肿瘤微环境。

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2025-01-01 Epub Date: 2024-08-16 DOI: 10.1002/med.22072

Suraj Kumar Modi, Pragyan Mohapatra, Priya Bhatt, Aishleen Singh, Avanish Singh Parmar, Aniruddha Roy, Vibhuti Joshi, Manu Smriti Singh

{"title":"Targeting tumor microenvironment with photodynamic nanomedicine.","authors":"Suraj Kumar Modi, Pragyan Mohapatra, Priya Bhatt, Aishleen Singh, Avanish Singh Parmar, Aniruddha Roy, Vibhuti Joshi, Manu Smriti Singh","doi":"10.1002/med.22072","DOIUrl":"10.1002/med.22072","url":null,"abstract":"Photodynamic therapy (PDT) is approved for the treatment of certain cancers and precancer lesions. While early Photosensitizers (PS) have found their way to the clinic, research in the last two decades has led to the development of third-generation PS, including photodynamic nanomedicine for improved tumor delivery and minimal systemic or phototoxicity. In terms of nanoparticle design for PDT, we are witnessing a shift from passive to active delivery for improved outcomes with reduced PS dosage. Tumor microenvironment (TME) comprises of a complex and dynamic landscape with myriad potential targets for photodynamic nanocarriers that are surface-modified with ligands. Herein, we review ways to improvise PDT by actively targeting nanoparticles (NPs) to intracellular organelles such as mitochondria or lysosomes and so forth, overcoming the limitations caused by PDT-induced hypoxia, disrupting the blood vascular networks in tumor tissues-vascular targeted PDT (VTP) and targeting immune cells for photoimmunotherapy. We propose that a synergistic outlook will help to address challenges such as deep-seated tumors, metastasis, or relapse and would lead to robust PDT response in patients.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":" ","pages":"66-96"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141994885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Canonical effects of cytokines on glomerulonephritis: A new outlook in nephrology. 细胞因子对肾小球肾炎的典型影响：肾脏病学的新前景

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2025-01-01 Epub Date: 2024-08-20 DOI: 10.1002/med.22074

Sepideh Zununi Vahed, Seyed Mahdi Hosseiniyan Khatibi, Mohammadreza Ardalan

引用次数: 0

Indirect influence on the BDNF/TrkB receptor signaling pathway via GPCRs, an emerging strategy in the treatment of neurodegenerative disorders. 通过 GPCRs 间接影响 BDNF/TrkB 受体信号通路，这是治疗神经退行性疾病的一种新兴策略。

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2025-01-01 Epub Date: 2024-08-24 DOI: 10.1002/med.22075

Mirjana Antonijevic, Patrick Dallemagne, Christophe Rochais

引用次数: 0

The recent advance and prospect of poly(ADP-ribose) polymerase inhibitors for the treatment of cancer. 聚（ADP-核糖）聚合酶抑制剂治疗癌症的最新进展和前景。

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2025-01-01 Epub Date: 2024-08-24 DOI: 10.1002/med.22069

Yi-Ru Bai, Wei-Guang Yang, Rui Jia, Ju-Shan Sun, Dan-Dan Shen, Hong-Min Liu, Shuo Yuan

{"title":"The recent advance and prospect of poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.","authors":"Yi-Ru Bai, Wei-Guang Yang, Rui Jia, Ju-Shan Sun, Dan-Dan Shen, Hong-Min Liu, Shuo Yuan","doi":"10.1002/med.22069","DOIUrl":"10.1002/med.22069","url":null,"abstract":"Chemotherapies are commonly used in cancer therapy, their applications are limited to low specificity, severe adverse reactions, and long-term medication-induced drug resistance. Poly(ADP-ribose) polymerase (PARP) inhibitors are a novel class of antitumor drugs developed to solve these intractable problems based on the mechanism of DNA damage repair, which have been widely applied in the treatment of ovarian cancer, breast cancer, and other cancers through inducing synthetic lethal effect and trapping PARP-DNA complex in BRCA gene mutated cancer cells. In recent years, PARP inhibitors have been widely used in combination with various first-line chemotherapy drugs, targeted drugs and immune checkpoint inhibitors to expand the scope of clinical application. However, the intricate mechanisms underlying the drug resistance to PARP inhibitors, including the restoration of homologous recombination, stabilization of DNA replication forks, overexpression of drug efflux protein, and epigenetic modifications pose great challenges and desirability in the development of novel PARP inhibitors. In this review, we will focus on the mechanism, structure-activity relationship, and multidrug resistance associated with the representative PARP inhibitors. Furthermore, we aim to provide insights into the development prospects and emerging trends to offer guidance for the clinical application and inspiration for the development of novel PARP inhibitors and degraders.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":" ","pages":"214-273"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Natural and synthetic 5-(3'-indolyl)oxazoles: Biological activity, chemical synthesis and advanced molecules. 天然和合成的 5-(3'-吲哚基)恶唑：生物活性、化学合成和高级分子。

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2025-01-01 Epub Date: 2024-08-16 DOI: 10.1002/med.22078

Jing-Rui Liu, En-Yu Jiang, Otgonpurev Sukhbaatar, Wei-Hua Zhang, Ming-Zhi Zhang, Guang-Fu Yang, Yu-Cheng Gu

{"title":"Natural and synthetic 5-(3'-indolyl)oxazoles: Biological activity, chemical synthesis and advanced molecules.","authors":"Jing-Rui Liu, En-Yu Jiang, Otgonpurev Sukhbaatar, Wei-Hua Zhang, Ming-Zhi Zhang, Guang-Fu Yang, Yu-Cheng Gu","doi":"10.1002/med.22078","DOIUrl":"10.1002/med.22078","url":null,"abstract":"5-(3'-Indolyl)oxazole moiety is a privileged heterocyclic scaffold, embedded in many biologically interesting natural products and potential therapeutic agents. Compounds containing this scaffold, whether from natural sources or synthesized, have demonstrated a wide array of biological activities. This has piqued the interest of synthetic chemists, leading to a large number of reported synthetic approaches to 5-(3'-indolyl)oxazole scaffold in recent years. In this review, we comprehensively overviewed the different biological activities and chemical synthetic methods for the 5-(3'-indolyl)oxazole scaffold reported in the literatures from 1963 to 2024. The focus of this study is to highlight the significance of 5-(3'-indolyl)oxazole derivatives as the lead compounds for the lead discovery of anticancer, pesticidal, antimicrobial, antiviral, antioxidant and anti-inflammatory agents, to summarize the synthetic methods for the 5-(3'-indolyl)oxazole scaffold. In addition, the reported mechanism of action of 5-(3'-indolyl)oxazoles and advanced molecules studied in animal models are also reviewed. Furthermore, this review offers perspectives on how 5-(3'-indolyl)oxazole scaffold as a privileged structure might be exploited in the future.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":" ","pages":"97-143"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141994884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future. 临床上治疗心脏代谢疾病的胰岛素疗法：过去、现在和未来。

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2025-01-01 Epub Date: 2024-08-14 DOI: 10.1002/med.22070

James P Psaltis, Jessica A Marathe, Mau T Nguyen, Richard Le, Christina A Bursill, Chinmay S Marathe, Adam J Nelson, Peter J Psaltis

{"title":"Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future.","authors":"James P Psaltis, Jessica A Marathe, Mau T Nguyen, Richard Le, Christina A Bursill, Chinmay S Marathe, Adam J Nelson, Peter J Psaltis","doi":"10.1002/med.22070","DOIUrl":"10.1002/med.22070","url":null,"abstract":"Among newer classes of drugs for type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are incretin-based agents that lower both blood sugar levels and promote weight loss. They do so by activating pancreatic GLP-1 receptors (GLP-1R) to promote glucose-dependent insulin release and inhibit glucagon secretion. They also act on receptors in the brain and gastrointestinal tract to suppress appetite, slow gastric emptying, and delay glucose absorption. Phase 3 clinical trials have shown that GLP-1 RAs improve cardiovascular outcomes in the setting of T2DM or overweight/obesity in people who have, or are at high risk of having atherosclerotic cardiovascular disease. This is largely driven by reductions in ischemic events, although emerging evidence also supports benefits in other cardiovascular conditions, such as heart failure with preserved ejection fraction. The success of GLP-1 RAs has also seen the evolution of other incretin therapies. Tirzepatide has emerged as a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA, with more striking effects on glycemic control and weight reduction than those achieved by isolated GLP-1R agonism alone. This consists of lowering glycated hemoglobin levels by more than 2% and weight loss exceeding 15% from baseline. Here, we review the pharmacological properties of GLP-1 RAs and tirzepatide and discuss their clinical effectiveness for T2DM and overweight/obesity, including their ability to reduce adverse cardiovascular outcomes. We also delve into the mechanistic basis for these cardioprotective effects and consider the next steps in implementing existing and future incretin-based therapies for the broader management of cardiometabolic disease.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":" ","pages":"29-65"},"PeriodicalIF":10.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11638809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141974647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

α-Synuclein in Parkinson's Disease: From Bench to Bedside.

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2024-12-20 DOI: 10.1002/med.22091

Gabriele Bellini, Vanessa D'Antongiovanni, Giovanni Palermo, Luca Antonioli, Matteo Fornai, Roberto Ceravolo, Nunzia Bernardini, Pascal Derkinderen, Carolina Pellegrini

{"title":"α-Synuclein in Parkinson's Disease: From Bench to Bedside.","authors":"Gabriele Bellini, Vanessa D'Antongiovanni, Giovanni Palermo, Luca Antonioli, Matteo Fornai, Roberto Ceravolo, Nunzia Bernardini, Pascal Derkinderen, Carolina Pellegrini","doi":"10.1002/med.22091","DOIUrl":"https://doi.org/10.1002/med.22091","url":null,"abstract":"α-Synuclein (α-syn), a pathological hallmark of PD, is emerging as a bridging element at the crossroads between neuro/immune-inflammatory responses and neurodegeneration in PD. Several evidence show that pathological α-syn accumulates in neuronal and non-neuronal cells (i.e., neurons, microglia, macrophages, skin cells, and intestinal cells) in central and peripheral tissues since the prodromal phase of the disease, contributing to brain pathology. Indeed, pathological α-syn deposition can promote neurogenic/immune-inflammatory responses that contribute to systemic and central neuroinflammation associated with PD. After providing an overview of the structure and functions of physiological α-syn as well as its pathological forms, we review current studies about the role of neuronal and non-neuronal α-syn at the crossroads between neuroinflammation and neurodegeneration in PD. In addition, we provide an overview of the correlation between the accumulation of α-syn in central and peripheral tissues and PD, related symptoms, and neuroinflammation. Special attention was paid to discussing whether targeting α-syn can represent a suitable therapeutical approach for PD.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142862708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0